Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

Bibliography

• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MHA, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Sartor AO, Oudard S, Ozguroglu M. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9]. Presented at the American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Symposium, 5 – 7 March 2010, San Francisco, California, USA
   Google Scholar
• de Bono J, Logothetis CJ, Fizazi K, Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized, double-blind, placebo-controlled Phase III study [abstract LBA5]. Presented at the 35th ESMO Congress; 11 October 2010, Milan, Italy
   Google Scholar
• Berthold DR, Pond GR, de Wit R, Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or viceversa. Ann Oncol 2008;19:1749-53
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase II study. Eur Urol 2008;54:1089-94
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci MA, A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010;28(20 Suppl): abstract LBA4511
   Google Scholar
• Ebos JM, Lee CR, Bogdanovic E, Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008;68:521-9
   PubMed Web of Science ®Google Scholar
• Kong D, Wang Z, Sarkar SH, Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008;26:1425-35
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Guerin O, Formento P, Lo Nigro C, Supra-additive antitumor effect of sunitinib malate (SU11248) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134:51-7
   PubMed Web of Science ®Google Scholar
• Cumashi A, Tinari N, Rossi C, Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270:229-33
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Regan MM, Oh WK, Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Periman PO, Bernold D, Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2009;21:319-24
   Google Scholar
• Bubley GJ, Carducci M, Dahut W, Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 1999;17:3461-7
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research involving human subjects. Available from: http://www.wma.net/e/policy/b3.htm [Last accessed 15 January 2009]
   Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase II study. Eur Urol 2008;54:1089-94
   PubMed Web of Science ®Google Scholar
• Horti J, Widmark A, Stenzl A, A randomized, double-blind, placebo-controlled Phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 2009;24:175-80
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Liu G, Hutson T, Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC) [abstract 5166J]. Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Aragon-Ching JB, Jain L, Gulley JL, Final analysis of a Phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009;103:1636-40
   PubMed Web of Science ®Google Scholar
• Nelius T, Klatte T, de Riese W, Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2009;27:363-7
   Google Scholar
• Escudier B, Roigas J, Gillessen S, Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
   PubMed Web of Science ®Google Scholar
• Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008;53:6-9
   PubMed Web of Science ®Google Scholar
• Georgiou HD, Namdarian B, Corcoran NM, Circulating endothelial cells as biomarkers of prostate cancer. Nat Clin Pract Urol 2008;5:445-54
   PubMedGoogle Scholar